|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0033147,
umls-concept:C0035015,
umls-concept:C0086418,
umls-concept:C0108793,
umls-concept:C0332835,
umls-concept:C0522537,
umls-concept:C1545588,
umls-concept:C1548437,
umls-concept:C1882687,
umls-concept:C1882923,
umls-concept:C2350483
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2000-1-24
|
|
pubmed:abstractText |
Production of transgenic pigs for multiple transgenes is part of a potential strategy to prevent immunological events involved in xenograft rejection. Use of a genetically engineerable rodent as a donor in primates could allow testing in vivo of the effects of different transgenes on controlling xenograft rejection. As a first step in the development of a donor containing multiple transgenes, transgenic rats for human decay-accelerating factor (DAF) were used as heart donors to test their resistance against complement (C)-mediated rejection by non-human primates.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-10092791,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-10330992,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-1280224,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-1580328,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-1871792,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-4355998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-6211481,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7482724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7504304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7506033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7526391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7527603,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7585088,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7839454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-7974711,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-8108871,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-8610385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-8610425,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-8629288,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-8755162,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9000677,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9256173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9355835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9392299,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9539095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9541506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9546786,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9565596,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9579856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9665072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9665074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10551903-9665076
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1076-1551
|
|
pubmed:author |
pubmed-author:AnegonII,
pubmed-author:AudetMM,
pubmed-author:AzimzadehAA,
pubmed-author:CharreauBB,
pubmed-author:CowanPP,
pubmed-author:IjzermansJJ,
pubmed-author:MénoretSS,
pubmed-author:MarquetRR,
pubmed-author:PearseMM,
pubmed-author:SoulillouJ PJP,
pubmed-author:TessonLL,
pubmed-author:VerbakelCC,
pubmed-author:WolfPP,
pubmed-author:d'ApiceAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
617-30
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10551903-Animals,
pubmed-meshheading:10551903-Animals, Genetically Modified,
pubmed-meshheading:10551903-Antibodies,
pubmed-meshheading:10551903-Antigens, CD55,
pubmed-meshheading:10551903-Endothelium,
pubmed-meshheading:10551903-Female,
pubmed-meshheading:10551903-Graft Rejection,
pubmed-meshheading:10551903-Heart Transplantation,
pubmed-meshheading:10551903-Humans,
pubmed-meshheading:10551903-Immunohistochemistry,
pubmed-meshheading:10551903-Macaca fascicularis,
pubmed-meshheading:10551903-Male,
pubmed-meshheading:10551903-Myocardium,
pubmed-meshheading:10551903-Necrosis,
pubmed-meshheading:10551903-Neutrophils,
pubmed-meshheading:10551903-Perfusion,
pubmed-meshheading:10551903-Rats,
pubmed-meshheading:10551903-Rats, Inbred Strains,
pubmed-meshheading:10551903-Rats, Sprague-Dawley,
pubmed-meshheading:10551903-Transgenes,
pubmed-meshheading:10551903-Transplantation, Heterologous
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates.
|
|
pubmed:affiliation |
INSERM U437 "Immunointervention en Allo et Xénotransplantation" and Institut de Transplantation et de Recherche en Transplantation, Nantes, France.
|
|
pubmed:publicationType |
Journal Article
|
